SWOG clinical trial number
S0014

Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High Risk Localized Aggressive Histologies of Non-Hodgkin’s Lymphoma, Phase II

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Published
Abbreviated Title
NON-HODGKIN'S: CHOP with concurrent rituximab plus IFR
Activated
04/01/2000
Closed
01/15/2002
Participants
NCORP, Members, Medical Oncologists, Pathologists

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine Doxorubicin Rituximab Radiation Therapy CHOP RT

Other Clinical Trials

S2308
SWOG Clinical Trial Number

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)
Lymphoma
Activated
08/01/2024
22% Accrual
Accrual
22%
Open
Phase
S2207
SWOG Clinical Trial Number

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase